Plus: NAD+ and the brain’s cellular antennas, happiness, blood pressure, and life inside the cell.
Is there a topic that you’d like to see more of in The Abstract? Drop us a line at [hidden]. Want to get The Abstract in your inbox? Sign up here.
ELYSIUM
This month, researchers test one of longevity science’s boldest ideas in a human randomized trial, microscopists reveal the astonishing machinery inside living cells, and a mouse study connects NAD+ with the tiny “antennas” that help neurons maintain cellular health. We’re also reading what 600 collective years of happiness research taught the scientists themselves—and why blood-pressure advice may need to focus on what we add to our diets as well as what we remove.
Cellular senescence is a stress response that permanently stops damaged cells from dividing. As senescent cells build up with age, they can release inflammatory signals that disrupt nearby tissue. Senolytics aim to clear these cells while sparing healthy ones.
Small early studies paired two senolytics: dasatinib (D), a prescription cancer drug, and quercetin (Q), a plant compound in the flavonoid family found in apples and onions. They focused on safety and markers of senescence. A new phase 2 trial randomly assigned 31 people with metabolic dysfunction-associated steatohepatitis (MASH), a liver disease marked by inflammation and scarring, to receive the D+Q combination intermittently or a placebo.
After 21 weeks, liver biopsies showed that fibrosis improved by at least one stage without worsening MASH in 47% of the treatment group versus 7% of the placebo group. MASH resolved in 53% versus 7%, respectively. Gene activity linked to senescence and fibrosis also declined in liver cells.
Adverse events were more common with treatment—reported by 82% of participants versus 43% of those receiving placebo—although researchers said they were temporary and resolved without ongoing treatment. The findings suggest that targeting cellular senescence, a hallmark of aging, may improve disease outcomes in people. But larger, longer trials across multiple sites are needed to confirm the liver benefits and determine whether they outweigh the risks.
The Expert’s Take:
“This study represents an encouraging step toward translating our understanding of cellular senescence into meaningful clinical benefits. What makes these findings particularly compelling is that the improvements in liver health were accompanied by molecular changes consistent with reduced senescence and fibrosis. While the trial was small and the higher incidence of adverse events warrants caution, the results provide early evidence that targeting a fundamental mechanism of aging may have therapeutic benefits. Larger studies will be essential to establish the long-term safety and efficacy of this D+Q approach.”
Lynne Chang, Ph.D.
VP, Product Development, Elysium Health
 
 
E
 
facebook   instagram   linkedin   attentive
 
© 2026 Elysium Health Inc., 434 Broadway, Floor 2, New York, NY 10013

Call or text: (888) 220-6436        [hidden]        Unsubscribe        View in Your Browser

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to screen, diagnose, treat, cure, or prevent any disease or condition or assess risk of any disease or condition. If pregnant or nursing, consult with your physician before using.